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OBJECTIVES: The aim of this study is to estimate the cost-
effectiveness ratio of Duloxetine compared to Venlafaxine in the
management of major depression in Portugal. A model developed
by MEDTAP International Inc. was adapted in order to reﬂect
clinical practice in Portugal. METHODS: The model allows for
the estimation of costs, QALY, the proportion of patients achiev-
ing remission, and the average time spent in remission by each
patient during one year. The societal perspective was adopted. In
each cycle a patient may drop-out, achieve remission, respond to
treatment not achieving remission, or have no response. Clinical
evaluation is based on patients’ scores in the Hamilton scale.
Patients that do not achieve remission may have their dose
adjusted, switch to or add another anti-depressant. Clinical data
was taken from a randomized controlled trial between Duloxet-
ine and Venlafaxine. Results show that Duloxetine allows more
patients to achieve remission, despite the fact that less patients
achieve response. Duloxetine is also associated with a higher
proportion of patients with adverse events. Recurrence and
relapse rates were taken from the literature. Quality of life and
resource consumption data were collected through a Delphi
panel of psychiatrists with large clinical experience. Ofﬁcial
sources were used to get unit costs. RESULTS: Patient that start
treatment with Duloxetine spend 34.5 weeks in remission, with
83.9% achieving remission at the end of the period. As a conse-
quence, Duloxetine enables 0.708 QALYs per patient. Those
who start treatment with Venlafaxine stay in remission during 34
weeks, with 83.5% achieving remission at the end of the period.
Therefore, Venlafaxine treated patients beneﬁt from 0.698
QALYs. Duloxetine also allows for savings in resources used. It
implies a total expenditure of €1126 per patient while Venlafax-
ine related expenditure equates to €1231. CONCLUSIONS:
Duloxetine is more effective and less costly, being a dominant
alternative.
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OBJECTIVES: While the substantial health care cost of depres-
sion in the workplace is well documented, less is known about
the impact of depression severity on workplace burden. The
objective is to document workplace burden of major depressive
disorder (MDD) by severity. METHODS: Using U.S. data from
the National Comorbidity Survey-Replication, workforce
respondents (n = 4465) were classiﬁed into clinical severity cat-
egories (not clinically depressed, mild, moderate, severe) using
standard scales (CIDI/QIDS-SR). Outcomes included employ-
ment status (employed, disabled, unemployed), workplace per-
formance (measured as hours worked, self-rated performance,
days of missed work), and workplace burden (estimated by mul-
tiplying work hours lost by self-reported hourly income, from
HPQ). Outcomes were compared across depression severity
groups using multivariate models that adjusted for demographic
characteristics. Total monthly US burden of reduced work and
performance was estimated through extrapolation using govern-
ment workforce statistics. RESULTS: Among the 539 depressed
respondents, 13.8% were mild, 38.5% moderate and 47.7%
severely depressed. Respondents shared similar demographic
characteristics across severity levels. Depressed respondents were
2.6 times more likely to be unemployed/disabled than non-
depressed respondents (p < 0.001). The prevalence rates of
unemployment/disability increased with depression severity:
15.7%, 23.3% and 31.3% for mild, moderate and severely
depressed respondents respectively (p < 0.01). Moderately and
severely depressed employed respondents were 4–5% less pro-
ductive than mildly depressed/non-depressed respondents (p <
0.01). Severity is negatively associated with work performance.
Compared to non-depressed respondents, mildly depressed
respondents have reduced monthly workplace performance by
3.0 hours (not statistically signiﬁcant), vs.12.0 hours (14.8
hours) for moderately (severely) depressed respondents (p <
0.001) The monthly cost of lost performance was $188 ($199)
per moderately (severely) depressed worker; the total monthly
U.S. burden of reduced work and performance is $2.1 billion/
month. CONCLUSIONS: Among MDD respondents in the
workforce, there was a positive association between depression
severity and rates of unemployment and disability. Depression is
also negatively associated with work performance.
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OBJECTIVES: Cost analysis of the changes in hospitalisation for
patients with schizophrenia in Spain over a 25-year period
(1980–2004). METHODS: Cost analysis of the hospitalisation
for patients with schizophrenia over a 25-year period based on
the data exploited from the Spanish National hospital utilization
databases: Minimum Basic Data Set and Survey of Hospital
Morbidity. Taking into account the changes in the number of
admission episodes, average length of stay (LOS) of such epi-
sodes, and costs generated per stay, an estimation of the varying
hospitalisation costs in this period was carried out. RESULTS:
Our data shows that the trend in hospitalisation rates for schizo-
phrenics has increased over the entire period (3.70 in 1980 to
5.89 in 2004). LOS has substantially decreased during the study
period from 148 days in 1980 to 36 days in 2004. The estimated
cost per day in a psychiatric hospital for a schizophrenic patient
in Spain in the year 2000 was €215.60. Some factors affecting the
cost of inpatient treatment has been the evolution, consumption
pattern and pharmaceutical cost of the antipsychotic drugs used
in the treatment of these patients. From 1990–2001, antipsy-
chotic consumption has almost doubled from 3.31 DID (Daily
deﬁned dose, DDD, per 1000 inhabitants and per day of treat-
ment) to 6.04 DID. The cost of these drugs has increased 13
times, mainly due to the increase in the cost of atypical antipsy-
chotics which has risen from representing less than 1% of the
total cost in 1993 to representing 92% in 2001. The DDD cost
has risen, in constant euros, from, €6.48 in 1990 to €20.31 in
2001. In addition, as a growing number of patients are being
taken care of in the community, as supported by the deinstitu-
tionalisation process, admissions into other types of institutions
should be considered. There are studies showing an increase in
the number of places in residential care and supervised and
supported housing, having doubled in Spain from 5.1 per
100.000 population in 1990 to 10.6 in 2006. Of course, the costs
per day vary greatly depending on the institution where the
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